Immatics FY2025 EPS Forecast Reduced by Cantor Fitzgerald

Key Points

• Analysts at Cantor Fitzgerald have reduced their FY2025 earnings per share estimate for Immatics to ($2.15), down from a previous estimate of ($1.40).
• Immatics reported a loss of ($0.66) EPS for the last quarter, failing to meet the consensus estimate of ($0.38).
• Institutional investors now hold 64.41% of Immatics' stock, with significant increases in holdings from firms like T. Rowe Price Investment Management.

Immatics N.V. (NASDAQ:IMTX - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Immatics in a research report issued to clients and investors on Thursday, August 14th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($2.15) for the year, down from their prior estimate of ($1.40). The consensus estimate for Immatics' current full-year earnings is ($0.72) per share. Cantor Fitzgerald also issued estimates for Immatics' FY2026 earnings at ($1.55) EPS.

Other equities analysts have also recently issued reports about the stock. Zacks Research cut shares of Immatics from a "hold" rating to a "strong sell" rating in a report on Friday, August 15th. Wall Street Zen cut shares of Immatics from a "hold" rating to a "strong sell" rating in a research note on Thursday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Immatics in a research note on Wednesday, May 28th. They set a "buy" rating and a $10.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $14.67.

Immatics Price Performance

Shares of NASDAQ IMTX traded up $0.0860 during mid-day trading on Monday, reaching $5.7160. 46,550 shares of the company traded hands, compared to its average volume of 757,879. The stock has a fifty day simple moving average of $6.01 and a 200-day simple moving average of $5.21. The firm has a market cap of $694.78 million, a PE ratio of -8.78 and a beta of 0.93. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $13.09.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.28). The business had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%.

Hedge Funds Weigh In On Immatics

Several large investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. raised its position in Immatics by 38.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock worth $66,194,000 after purchasing an additional 4,072,226 shares during the last quarter. Wellington Management Group LLP increased its position in Immatics by 7.6% in the 4th quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company's stock valued at $74,071,000 after buying an additional 736,709 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Immatics by 12.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,275,830 shares of the company's stock valued at $51,731,000 after acquiring an additional 832,432 shares in the last quarter. Vestal Point Capital LP increased its holdings in Immatics by 14.6% during the 1st quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company's stock worth $32,439,000 after purchasing an additional 917,700 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP increased its stake in Immatics by 38.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company's stock valued at $38,496,000 after buying an additional 1,509,547 shares during the last quarter. 64.41% of the stock is currently owned by institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.